Plasma membrane SK2 channel activity regulates migration and chemosensitivity of high‐grade serous ovarian cancer cells
Molecular Oncology · 2024-08 · 18 (8) · 1853-1865
DOI: 10.1002/1878-0261.13631 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 13.03.2024. Verfasst von Olivier Romito und 9 weiteren Autor:innen. Beteiligte Einrichtung: Inserm UMR 1069, Nutrition Croissance Cancer, Faculté de Médecine, Université de Tours, Tours, France. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Cell Movement, Small-Conductance Calcium-Activated Potassium Channels, Cell Membrane. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conseil Régional du Centre-Val de Loire, Institut National de la Santé et de la Recherche Médicale, Canceropôle Grand Ouest.
Abstract (Originalsprache)
No data are currently available on the functional role of small conductance Ca 2+ ‐activated K + channels (SKCa) in ovarian cancer. Here, we characterized the role of SK2 (KCa2.2) in ovarian cancer cell migration and chemosensitivity. Using the selective non‐cell‐permeant SK2 inhibitor Lei‐Dab7, we identified functional SK2 channels at the plasma membrane, regulating store‐operated Ca 2+ entry (SOCE) in both cell lines tested (COV504 and OVCAR3). Silencing KCNN2 with short interfering RNA (siRNA), or blocking SK2 activity with Lei‐Dab7, decreased cell migration. The more robust effect of KCNN2 knockdown compared to Lei‐Dab7 treatment suggested the involvement of functional intracellular SK2 channels in both cell lines. In cells treated with lysophosphatidic acid (LPA), an ovarian cancer biomarker of progression, SK2 channels are a key player of LPA pro‐migratory activity but their role in SOCE is abolished. Concerning chemotherapy, SK2 inhibition increased chemoresistance to Taxol® and low KCNN2 mRNA expression was associated with the worst prognosis for progression‐free survival in patients with serous ovarian cancer. The dual roles of SK2 mean that SK2 activators could be used as an adjuvant chemotherapy to potentiate treatment efficacy and SK2 inhibitors could be administrated as monotherapy to limit cancer cell dissemination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Inserm UMR 1069, Nutrition Croissance Cancer, Faculté de Médecine, Université de Tours, Tours, France.
- Réseau Molécules Marines, Métabolisme et Cancer and Réseau CasTHOR Cancéropôle Grand Ouest, Tours, France.
- CHRU de Tours, Service de Gynécologie et d'Obstétrique, Tours, France.
- UPMC Hillman Cancer Center, Division of Hematology & Oncology, Department of Medicine, University of Pittsburgh, PA, USA.
- Department of Pharmacology and Chemical Biology, Vascular Medicine Institute, University of Pittsburgh, PA, USA.
ORCID-Profile: Marie Potier-Cartereau
Förderung
- Conseil Régional du Centre-Val de Loire
- Institut National de la Santé et de la Recherche Médicale
- Canceropôle Grand Ouest
- University of Tours
- NHLBI NIH HHS
- Ligue Contre le Cancer
- Université François-Rabelais
Zitieren
APA
Romito, O., Lemettre, A., Chantôme, A., Champion, O., Couty, N., Ouldamer, L., Hempel, N., Trebak, M., Goupille, C., & Potier-Cartereau, M. (2024). Plasma membrane SK2 channel activity regulates migration and chemosensitivity of high‐grade serous ovarian cancer cells. Molecular Oncology, 18(8), 1853-1865. https://doi.org/10.1002/1878-0261.13631
Vancouver
Romito O, Lemettre A, Chantôme A, Champion O, Couty N, Ouldamer L, et al. Plasma membrane SK2 channel activity regulates migration and chemosensitivity of high‐grade serous ovarian cancer cells. Molecular Oncology. 2024;18(8):1853-1865. doi:10.1002/1878-0261.13631
BibTeX
@article{Romito2024,
author = {Romito, Olivier and Lemettre, Aude and Chantôme, Aurélie and Champion, Ophélie and Couty, Noémie and Ouldamer, Lobna and Hempel, Nadine and Trebak, Mohamed and Goupille, Caroline and Potier-Cartereau, Marie},
title = {Plasma membrane SK2 channel activity regulates migration and chemosensitivity of high‐grade serous ovarian cancer cells},
journal = {Molecular Oncology},
year = {2024},
volume = {18},
number = {8},
pages = {1853--1865},
doi = {10.1002/1878-0261.13631}
}
EUVIMED